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ABSTRACT:
Patients of Non-Hodgkin’s lymphomas may develop neurological signs and symptoms. This case is of a 76 year old
male recently diagnosed with Non-Hodgkin’s lymphoma and on chemotherapy who presented with sudden bilateral leg
weakness and inability to walk. The signs and symptoms, neurological examinations and Nerve conduction studies
revealed a polyneuropathy which was consistent with Guillain-Barré syndrome (GBS). This has been seen in patients
with Hodgkin's lymphoma but is rare in NHL.
Keywords: Non-Hodgkin lymphoma (NHL), Guillain–Barré syndrome (GBS), demyelinating polyneuropathy,
chemotherapy.

INTRODUCTION: Non-Hodgkin lymphoma (NHL) is
considered as a malignancy which starts from white
blood cells referred to as lymphocytes, which are
undoubtedly an essential part of the body’s defense
system. NHL most frequently affects adults, however
even children can be affected. NHL typically starts in
lymph nodes or other lymphatic tissue but occasionally
it can also affect the skin. Lymphomas can occur
anyplace within the body where lymphatic tissue is
present. Lymph nodes, bone marrow, adenoids and
tonsils, spleen,thymus and alimentary canal are the
major sites of the lymphoid tissue. The type of
lymphoma depends on the kind of lymphocyte affected
(B cells or T cells), how mature the cells are, when they
become cancerous and some other factors. Indolent
lymphomas develop and unfold gradually whereas
aggressive lymphomas grow and advance rapidly. In
NHL there's a subtle male to female preponderance
and the incidence rises with age particularly after forty
years(1).The neurological symptoms of NHL may
potentially include any sort of neurological symptom
from headaches to paralysis and meningism (2).
Different patterns of neurological disease in patients
with NHL have been seen, including direct
lymphomatous involvement of the peripheral nerves,
cord compression, and meningeal infiltration, spread to
cerebrum, as paraneoplastic
lymphomatous
involvement of the peripheral nerves. Peripheral
neuropathy is commonly caused by the toxic effect of
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chemotherapeutic drugs. Another reason behind
central nervous system damage is radiotherapy
(radiation myelopathy)(1,3). Paraneoplastic syndromes in
neurologic essence, such as Guillain-Barré syndrome
(GBS), are rare in NHL(1). Guillain–Barré syndrome
(GBS) is an auto immune disorder damaging the
peripheral nerves,manifesting as a rapid-onset muscle
weakness. The inceptive prodromes are generally
changes in sensation or pain in conjunction with
muscle weakness. GBS Immunopathology suggests
that this is sometimes prompted by infection or, less
commonly by surgery and also scarcely by vaccination.
The diagnosis is generally made by clinical exclusion of
alternate causes, and supported by tests like nerve
conduction studies (NCS) and examination of the
cerebrospinal fluid. GBS is the most common form of
acute flaccid paralysis, and has different clinical
subtypes are Acute inflammatory demyelinating
polyneuropathy (AIDP), Acute motor axonal neuropathy
(AMAN), acute motor and sensory axonal neuropathy
(AMSAN) or Pharyngeal-cervical-brachial variant.(4).
We present a case of NHL with GBS.
CASE REPORT:
A 76-years-old male with previous co-morbid of
hypertension for the last 5 years, on diet control, came
to the A n E of Shifa International Hospital in April
2019, with the complaint of lower back pain and
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sudden onset of bilateral lower limb weakness
associated with inability to walk on both legs for 3 days.
This was preceeded by leg pain . There were no other
complaints of bowel or urinary dysfuction, no speech or
swallowing difficulty, no upper limb weakness,seizures,
LOC, or fever. He also gives a history of intermittent
low back pain.This patient was already been diagnosed
as Non-hodgkin’s Lymphoma on right inguinal lymph
node biopsy on 3.11.2018 which showed “ Follicular
lymphoma ,WHO Grade 3A , Ki67 proliferative index
40%” .He had history of inguinal hernia operated 20
years back. He was in his usual state of health when
on 28.10.18 he noted a lump at the operation scar of
herniotomy. Visited a local hospital for follow up with his
surgeon. Initially an Ultrasound abdomen was done
which showed “ cholelithiasis, spleenomegaly with
hypoechoic areas in spleen and extensive
abdomino-pelvic lymphadenopathy” . He underwent
submandibular lymph node FNAC on 30.10.18 which
showed a “lymphoproliferative disorder”. He was
referred to Shifa International hospital on 5.11.2018
for further workup and treatment. CT Scan neck, soft
tissues, chest, abdomen and pelvis with contrast
performed on 17.11.2018 showed enlarged lymph
nodes in neck, bilateral axilla, mediastinum, in
abdomen and pelvis with mass effect on adjacent
visceras and vessels, finding’s likely of a Lymphoma.
Bone marrow biopsy and aspiration performed on
20.11.2018 showed a“ hypercellular marrow involved
by lymphoma”. Immunohistochemistry showed
CD20:positive, CD10:Positive, Ki67 ( proliferatie index)
30-40%. His first cycle of chemotherapy started on
21.11.2018. He had a total 6 cycles of R- CHOP,
(Rituximab,
Cyclophosphamide,
Vincrsitine,
Doxorubicin, Prednisone) Repeat CT scan of chest
,abdomen and pelvis on 9.2.2019 showed interval
increase in disease in mediastinal,retrocural,
peripancreatic and left paraaortic region,Some of left
axillary lymph nodes were reduced in number and size
while some are unchanged. Interval significant
reduction in size of lymph nodes in right axilla , along
internal iliac vessel and inguinal region,overall findings
were suggestive of a mixed reponse to treatment.
Repeat CT scan done on 20.3.19 showed interval
increase in size of cervical, left supraclavicular, left
axillary and mediastinal lymph nodes,interval increase
in lobulated necrotic nodular mass in left para aortic
and aorto caval region, interval increase in retrocural
nodal mass. Overall findings suggestive of interval
increase in disease process so the patient was shifted
to GDP (Gemcitabine, Dexamethasone and Cisplatin )
and had 1 cycle of GDP. His last session of
chemotherapy was done 10 days ago before his acute
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presentation in the emergency department.
On examination in ER the patient had a pulse of
99/min, breathing rate 18/min BP 100/65 mmHg,
sPO2% 91%. Was afebrile , GCS 15/15 and was having
a pain score of 2/10 on arrival. Chest had B/L equal air
entry. Pupils bilaterally equally reactive, pallor present,
had bilateral pedal edema but no specific findings in
abdomen. Neurological examination revealed intact
cerebellar and sensory sensations, mild thoraco-lumbar
spine tenderness, plantars bilateral mute, hyporeflexia
in reflexes of upper and lower limbs. Power was as
follows Upper limbs 5/5, 5/5. Lower Limbs Knees both
in flexion and extention 4+/5, 4+/5, Hips in extension
and flexion 3/5, 3/5, ankles dorsi and planterflextion
4/5, 4/5. Laboratory investigations were done which
showed TLC 14,270/UL, Hb 7.9 g/dL, Platelet count
14000/UL, Sodium 135mEq/L, potassium 3.5 mEq/L,
Chloride 99 mEq/L , Bicarbonate 24mmol/L. BUN
15mg/dL, Urea 32.1 mg/dL, creatinine 1.2 mg/dL. ALP
395 U/L.MRI Dorso lumbar spine with contrast showed
diffused heterogenous marrow signal with post contrast
enhancement at L1, T11, T10 and T8 vertebrae.
Disruption of the posterior cortex of L1 vertebrae with
soft tissue epidural compliment indenting the ventral
thecal sac on right. Small enhancing posterior epidural
component at level of L5. Multiple para aortic,
retrocaval and peripancreatic lymph nodes, lumbar disc
degenerative changes. Nerve Conduction studies were
then done and the report showed an abnormal study
findings were suggestive of mixed predominantly
demyelinating polyneuropathy, given the clinical history,
Guillain Barre Syndrome is a possibility. The results of
the nerve conduction studies were as follows: 1)
Bilateral median APB motor responses have
moderately prolonged distal latency, severely reduced
amplitude, conduction velocity and not recordable F
wave.2) Right ulnar ADM motor response has mildly
prolonged distal latency, moderately reduced
amplitude, conduction velocity and mildly prolonged F
wave. 3) Left ulnar ADM motor response has normal
distal latency, mildly reduced amplitude, normal
conduction velocity and F wave. 4) Right tibial motor
response has normal distal latency, severely reduced
amplitude, conduction velocity and not recordable F
wave. 5) Left Tibial and bilateral Peroneal EDB motor
are not recordable. 6) Bilateral peroneal TA motor
responses have normal distal latencies, severely
reduced amplitudes and normal conduction velocities.
7) Bilateral median , sural and superficial peroneal
sensory are not recordable. 8) Right ulnar sensory
response has moderately reduced latency, severely
reduced amplitude and moderately reduced conduction
velocity. 9) Left ulnar sensory response has moderately
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reduced latency, moderately reduced amplitude and
severely reduced conduction velocity. 10) Right radial
has technical difficulty. 11) Left radial sensory response
has normal latency, mildly reduced amplitude and
normal conduction velocity. The patient was diagnosed
with GBS and was advised PLEX but the patient and his
family refused Plasmapharesis, IVIG or any other
aggressive management. So the patient was put on
supportive care. On the 3rd day of admission the
neurological examination revealed GCS 15/15. Speech
and comprehension Normal, reflexes diminished,
plantar right downgoing, left equivocal, Power Upper
limbs 4+/5, 4+/5, lower limbs 4-/5, 4-/5.Patient was
discharged home in stable condition.

sensory or sensory motor neuropathy, plexopathy,
individual peripheral or cranial nerve deficit. Immune
response in both CNS and PNS is attributed to be the
most important cause of GBS. The tumors act as an
antigen, which initiates an immunological response.
Drugs causing neurological abnormalities are Vinca
alkaloids causing sensorimotor polyneuropathy,
cytarabine causing cerebellar dysfunction and
intrathecal methotrexate and cytarabine may cause
myelopathy(9). Pal PK studied clinical and
electrophysiological characteristics in vincristine
induced neuropathy. NCS show prolonged mean distal
latencies, decreased amplitude of Action potential,
unchanged conduction velocities concluding that
vincristine produces distal axonal sensorimotor
neuropathy predominantly involving large diameter
fibers(9,10). In our case the differentials included
demyelinating polyneuropathy (GBS), chemotherapy
drug toxicity, Cauda equina syndrome or intramedullary
lymphoma of the spinal cord. The clinical presentation
of no bladder or bowel dysfunction and MRI findings
excluded cauda equine syndrome. Also the MRI
dorsolumbar spine with contrast was not consistent
with intramedullary lymphoma of the spinal cord. Toxin
mediated polyneuropathy was ruled out based on
clinical features of diminished reflexes and NCS
studies. The NCS studies showed mixed but
predominantly
demyelinating
polyneuropathy
consistent with GBS. Plasma Exchange is
recommended as gold standard of care for the
treatment of GBS but randomized control trials have
shown that IVUG are at least equally effective. Plasma
exchange leads to faster improvement compared to
supportive care alone and is most effective when
treatment is initiated in the first 7 days after the start of
symptoms(8,11). In our case unfortunately the patient
refused treatment with either IVIG or PE and demanded
supportive care.

DISCUSSION:
GBS is an autoimmune idiopathic acute demyelinating
polyneuropathy. Two thirds of the cases are related to a
recent upper respiratory tract infection and G.I.T.
infection, most commonly associated with CMV, EBV
virus and
Campylobacter jejuni(5).GBS has been
associated with some systemic diseases like SLE,
Hodgkin’s Lymphoma and HIV. It is extremely rare in
NHL, occurring in less than 0.3% of the cases(1,6).
GBS presents as acute ascending polyneuropathy
predominantly motor paralysis. Varying degree of
sensory loss occurs but mostly in first few days and is
sometimes hardly detectable. Death occur due to the
involvement of the respiratory muscles. Oculomotor
nerve involvement occur in very severe cases. It should
be differentiated from other orthopedic and lumbar
diseases causing back pain as many patients presents
initially with generalized body and muscle aches
specially in the back, hip, thighs and lower limbs.
Clinically diminished and then absent deep tendon
reflexes is the most consistent finding of GBS. The
important investigations include Nerve conduction
studies and CSF examination. CSF is acellular or
contain a few lymphocytes while protein levels are
elevated. EMG and NCS studies have the following
findings consistent with GBS: slow conduction velocity,
reduction in amplitude of muscular action potentials,
conduction block in motor nerves, prolonged distal
latencies ( indicative of distal conduction block) and
prolonged or absent F waves ( indicative of involvement
of proximal parts of nerves and roots). All of these
showing focal demyelination(1). Patients with NHL may
present with neurological signs and symptoms. The
peripheral neuropathy is mostly due to the local
infiltration by lymphomatous cells or due to drug
toxicity. Infiltration of the CNS is diagnosed usually by
imaging techniques whereas peripheral nerve
involvement may present with generalized motor,
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CONCLUSION:
We believe that GBS though extremely rare in NHL, was
developed in this patient due to the immune
mechanisms triggered by NHL.GBS is commonly seen
in Hodgkin’s Lymphoma and post transplantation but
extremely rare in NHL. A few cases have been reported
showing GBS in association with diffuse large B cell
lymphoma, Burkitt Lymphoma and T/NK-cell lymphoma
(1,6,11,12)
.In our case GBS was associated with Follicular
lymphoma ( grade 3A).
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